Browse studies, page 1079

Page 1079 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets International journal of molecular sciences, 2023
• Novel Therapeutics for Type 2 Diabetes Mellitus-A Look at the Past Decade and a Glimpse into the Future Biomedicines, 2024
• GLP-1 receptor agonists beyond glycemic control: integrated cardio-renal-metabolic protection across the cardiovascular kidney metabolic continuum Cardiovascular diabetology. Endocrinology reports, 2026
• The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials BMC endocrine disorders, 2023
• Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference Current atherosclerosis reports, 2025
• Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial Journal of cardiac failure, 2023
• The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes Annals of Military and Health Sciences Research, 2024
• Cost‐Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2024
• The Impact of Empagliflozin on Renal Function and Kidney Injury Markers in Patients with Diabetic Nephropathy Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ), 2024
• Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data The Annals of Pharmacotherapy, 2019
• Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin Cardiovascular Diabetology, 2021
• Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure Journal of The American Geriatrics Society, 2022
• Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial European Heart Journal, 2022
• Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial Russian Journal of Cardiology, 2022
• Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data Diagnostics, 2026
• Evaluating the effects of empagliflozin in preventing myocardial injury in patients undergoing percutaneous coronary intervention: A double-blind, randomized clinical trial Journal of Cardiovascular and Thoracic Research, 2024
• Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone Nature, 2024
• A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study Cardiovascular diabetology, 2021
• Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease Clinics and research in hepatology and gastroenterology, 2024
• Empagliflozin increases plasma levels of citrulline, histidine, and α-aminobutyric acid in patients with type 2 diabetes: effects of a sodium-glucose co-transporter 2 inhibitor on the plasma amino acid profile Expert opinion on pharmacotherapy, 2024
• Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause Journal of the American Heart Association, 2023
• Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population Journal of cardiac failure, 2022
• Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: translational implications Canadian journal of physiology and pharmacology, 2018
• Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects Clinical therapeutics, 2015
• Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes Diabetes, obesity & metabolism, 2022
• Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population Frontiers in endocrinology, 2022
• Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus ESC heart failure, 2021
• Effect of SGLT2 Inhibition on Glucosuria During a Hyperglycemic Clamp in HNF1A-MODY (MODY3) and Type 2 Diabetes Diabetes care, 2025
• Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial Journal of Diabetes and Metabolic Disorders, 2024
• Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study Cardiovascular Diabetology, 2021
• 1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial 2020
• Evaluating the limited impact of therapy with empagliflozin on primary PCI patients' outcomes: the ELITE-PCI trial Cardiovascular Biomedicine Journal, 2025
• Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial Global Cardiology, 2025
• Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: a randomised trial Diabetes Research and Clinical Practice, 2023
• Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial Diabetes, obesity and metabolism, 2015
• Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study Diabetes, obesity & metabolism, 2024
• SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus Cell metabolism, 2019
• Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis International Journal of Cardiology: Heart & Vasculature, 2020
• Effectiveness of SGLT2 Inhibitors in Improving Functional Capacity and Reducing Hospitalizations in Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Randomized Controlled Trials Cureus, 2025
• Cost-effectiveness analysis and medication use for gangrene treatment in type 2 diabetes patients: A systematic literature review Pharmacia, 2025
• Abstract 14100: Which Sodium-Glucose Cotransporter 2 Inhibitors Agent is More Effective in Patients With Heart Failure? A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials Circulation, 2022
• The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials Medicina, 2023
• SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews BMJ open diabetes research & care, 2020
• Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review ESC heart failure, 2021
• Prognostic models for patients suffering a heart failure with a preserved ejection fraction: a systematic review ESC heart failure, 2024
• Utilization of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacoepidemiological Studies: A Systematic Review on Antiarrhythmic and Glucose-Lowering Medicines Frontiers in pharmacology, 2022
• Economic evaluation of adding dapagliflozin to standard care in the treatment of chronic kidney disease: a systematic review BMC nephrology, 2024
• The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta-regression analysis of randomized controlled trials Frontiers in endocrinology, 2023
• Recurrent Urinary tract infections and type 2 diabetes mellitus: a systematic review predominantly in women Frontiers in urology, 2023
• Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis Frontiers in cardiovascular medicine, 2022
• Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications Cardiovascular diabetology, 2025
• Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis Frontiers in cardiovascular medicine, 2024
• Genomic insights about the effect of sodium-glucose cotransporter 2 inhibitors: a systematic review Frontiers in genetics, 2025
• Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis BMJ open, 2026
• Systematic review of ocular and circulatory cytokines linking diabetic retinopathy to kidney disease Frontiers in endocrinology, 2026
• Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis Clinical drug investigation, 2018
• Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis Cardiovascular drugs and therapy, 2021
• Long-term efficacy of gliflozins versus gliptins for Type 2 Diabetes after metformin failure: a systematic review and network meta-analysis Revista da Associacao Medica Brasileira (1992), 2020
• Diabetes Treatment in the Elderly: Incorporating Geriatrics, Technology, and Functional Medicine Current diabetes reports, 2018
• Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials Frontiers in endocrinology, 2024
• The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials Annals of palliative medicine, 2021
• The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: A meta-analysis of randomized controlled trials Diabetes, obesity & metabolism, 2024
• Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials European Journal of Clinical Pharmacology, 2021
• 260 efficacy of SGLT2 inhibitors in patients with and without heart failure and across the spectrum of left ventricular ejection fraction: a systematic review and meta-analysis of randomized controlled trials European Heart Journal, Supplement, 2022
• Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials Heart Failure Reviews, 2022
• A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients Annals of Medicine and Surgery, 2026
• Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis International Journal of Cardiology Cardiovascular Risk and Prevention, 2026
• SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials Global Cardiology, 2023
• Comparative efficacy and safety of sodium–glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis Renal Failure, 2023
• Comparative safety of different recommended doses of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials Frontiers in Endocrinology, 2023
• Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China Frontiers in Public Health, 2025
• Effect of sodium-glucose cotransporter-2 inhibitor (SGLT2-i) in patients with LVAD: a systematic review and meta-analysis European Heart Journal, 2024
• Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis Frontiers in Endocrinology, 2024
• Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis BMC Endocrine Disorders, 2024
• A Network Meta-Analysis of the Efficacy and Safety of Empagliflozin at Different Doses in Patients with Diabetes Mellitus Based on Randomized Controlled Trials 2020
• Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients The Cochrane database of systematic reviews, 2020
• Effects of sodium-glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta-analysis of randomized controlled trials Journal of diabetes investigation, 2019
• Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Cardiovascular diabetology, 2021
• SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials Cardiovascular diabetology, 2020
• Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region: A meta-analysis Medicine, 2020
• Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis The Cochrane database of systematic reviews, 2021
• Effect of Ramadan fasting in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitors: A systematic review and meta-analysis Journal of diabetes investigation, 2022
• Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis PloS one, 2021
• Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients Scientific reports, 2021
• Metformin for preventing the progression of chronic kidney disease The Cochrane database of systematic reviews, 2024
• Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis Journal of diabetes, 2023
• Recent applications of quantitative systems pharmacology and machine learning models across diseases Journal of pharmacokinetics and pharmacodynamics, 2022
• Comparative cardiovascular outcomes of novel drugs as an addition to conventional triple therapy for heart failure with reduced ejection fraction (HFrEF): a network meta-analysis of randomised controlled trials Open heart, 2023
• Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis Journal of diabetes research, 2022
• Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis ESC heart failure, 2022
• Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials Cardiovascular diabetology, 2022
• Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Frontiers in endocrinology, 2020
• Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials Journal of diabetes investigation, 2021
• Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Journal of diabetes investigation, 2020
• Immunosuppressive therapy for IgA nephropathy in children The Cochrane database of systematic reviews, 2024
• Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials Acta diabetologica, 2021
• Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis PloS one, 2022
• Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis Frontiers in endocrinology, 2022
• Cognitive protection of incretin-based therapies in patients with type 2 diabetes mellitus: A systematic review and meta-analysis based on clinical studies Journal of diabetes investigation, 2023
• Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated meta-analysis ESC heart failure, 2022